Nearing 97, she’s universally praised, freshly republished, and (maybe even) more widely read than ever. She’s also a ...

Illexcor Therapeutics is a biopharmaceutical company dedicated to the creation of next-gen oral therapies to treat patients ...

India's Zydus Lifesciences declared it would purchase an 85.6 per cent ownership in France's Amplitude Surgical for 256.8 ...

Ahmedabad: Global lifesciences company, Zydus Lifesciences Limited, has announced the development of a combination vaccine against shigellosis and typhoid. Zydus will carry out early-stage development ...

Zydus will carry out early-stage development. (Image Credits: Pixabay) Zydus Lifesciences Limited on Tuesday announced its focus on the development of a combination vaccine against shigellosis and ...

Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid. The company, with support from the Gates Foundation, will carry out ...

The project is expected to get underway in March 2025. Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid. The company ...

High Conviction Stocks Idea Attributes-Company: a) Sound / resilient business; b) Consistent strong financials; c) High growth potential; and d) High return on invested capital.Industry: a) Market ...

Zydus Lifesciences announced today it will develop the world’s first combination vaccine targeting both typhoid fever and shigellosis, with financial backing from the Bill & Melinda Gates ...

Zydus Lifesciences is developing a combination vaccine targeting shigellosis and typhoid, with support from the Gates Foundation. The effort focuses on early-stage development and animal studies.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...